SAN DIEGO, Sept. 20, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced the formation of the new Excellagen Medical Advisory Board, comprising leading practitioners, clinicians and researchers with diversified expertise in the field of advanced wound care. The Medical Advisory Board will provide strategic feedback and guidance to the Company on its ongoing commercialization activities, post-marketing research, reimbursement strategies and educational opportunities for Cardium's new Excellagen advanced wound care product platform.
Since receiving FDA clearance for Excellagen, Cardium has established cGMP out-sourced manufacturing and supply with UK-based Angel Biotechnology, developed cold chain logistics and distribution with Smith Medial Partners, initiated a pathway toward securing private payer and government product reimbursement, including Centers for Medicare & Medicaid Services (CMS), and assembled an internal strategic and tactical sales and marketing team. The Company is currently engaged in physician relationship building, product sampling, practice integration and building a portfolio of physician case studies. As a result of Excellagen's FDA clearance labeling, it can now be marketed and sold for the treatment of a broad array of wounds including diabetic foot ulcers, pressure ulcers, venous ulcers, surgical, and other dermal wounds. In the U.S., the Company is initially focused on four vertical wound healing market channels: (1) podiatry, (2) wound care centers, hospitals, and long-term care facilities, (3) government agency providers (such as the U.S. Department of Veterans Affairs and Bureau of Indian Affairs), and (4) dermatology. Consistent with Cardium's business strategy, the Company is currently working with U.S. and international strategic players to establish representation, marketing and sales, or co-promotional arrangements, leading toward an expanded physician base, revenues, and monetization opportunities.
"We are pleased to have assembled such an impressive group of key opinion leaders and industry experts in the field of our initial target diabetic wound care market. The Medical Advisory Board's collective expertise, insights and practical clinical experience will be instrumental as we advance our commercialization efforts to better target the needs of wound care practitioners and patients who could benefit from our Excellagen wound care product," stated Christopher J. Reinhard, Cardium's Chairman and CEO.Excellagen Medical Advisory Board Members Rudolph C. Anderson, Jr., DPM, FAPWCA: Virginia Medical Alliance, Springfield, VA; Active Staff at Sentara Potomac Hospital, Virginia Hospital Center and INOVA Springfield Ambulatory Surgical Center Jay S. Berenter, DPM, FACFAS: Podiatrist and Chief, Podiatric Division Department of Orthopedics, Scripps Memorial Hospital, La Jolla, CA James Blaine, DPM: President and CEO of Limb Savers Podiatric Wound Care Center, Columbus, OH Anthony Cannizzaro, DPM, MPH, FAPWCA: Senior Clinical Consultant, Kaiser Permanente, Los Angeles, CA; CPMA Society President, Southern California Kaiser Permanente Podiatry Society; and Clinical Associate Professor of Podiatric Medicine and Surgery, Western University of Health Sciences, Pomona, CA John D. Halebian, DPM: Doctor of Podiatric Medicine, Henry Mayo Hospital, Valencia, CA; and Attending Staff Wound Care and Attending Physician, Henry Mayo Hospital Howard M. Kimmel, DPM: Louis Stokes Veterans Affiars Medical Center, Cleveland OH; Senior Clinical Instructor, Department of Surgery, Case Western Reserve University School of Medicine; Core Clinical Faculty, Ohio College of Osteopathic Medicine; Faculty Member, St. Vincent's Charity Residency Program; Chief of Podiatric Medicine and Surgery, Free Clinic of Cleveland; and Adjunct Clinical Professor of Surgery, Ohio College of Podiatric Medicine Lawrence A. Lavery, DPM, MPH, BS: Professor Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, TX and Vice Chair of Medical Affairs, Chronic Disease Specialists Eric J. Lullove, DPM, PA: Podiatric Medicine and Surgery Board Certified Wound Specialist, Boca Raton, FL; Speaker Bureau Member/Consultant for Cordis Corporation/Johnson & Johnson; and Active Surgical Staff Committee Member, West Boca Medical Center William D. McDonald, DPM: Doctor of Podiatric Medicine, Pacific Wound Center, Stockton, CA Jeffrey A. Ross, DPM, MD, FACFAS: Podiatric Medicine and Surgery, Houston, TX; Clinical Instructor Externship Program at Ohio College of Podiatric Medicine, Iowa College of Podiatric Medicine and Barry University College of Podiatric Sports Medicine Arthur J. Tallis, DPM: President and Medical Director, Associated Foot & Ankle Specialists, Phoenix, AZ; Physician Peer Review, Health Care Finance Commission; Physician Peer Review Panels of the Health Service Advisory Group and Mediq Review Services; and Sub-Investigator, Phoenix Center for Clinical Research David A. Yeager, DPM, FASPS, FACFAS: Podiatrist at KSB Foot and Ankle Center/Wound Care Center, Dixon, IL; Director of Podiatric Medical Education and Adjunct Professor, St. Joseph's Hospital Podiatric Surgical Residency; and Clinical Assistant Professor, Department of Family and Community Medicine, University of Illinois College of Medicine at Rockford Stephanie C. S. Wu, DPM: Associate Dean of Research and Associate Professor, Department of Stem Cell and Regenerative Medicine, Dr. William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine and Science, Chicago, IL; and Director of Educational Affairs and Outreach, Center for Lower Extremity Ambulatory Research (CLEAR) About Excellagen Excellagen is an FDA-cleared formulated collagen topical gel (2.6%) designed for use with debridement and engineered to support a favorable wound healing environment and platelet activation for non-healing lower extremity diabetic ulcers and other dermal wounds. Excellagen's unique high-molecular weight structured collagen formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and its viscosity-optimized gel formulation is designed for application at only one or two week intervals. Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.